Cassava Sciences' stock plummeted by over 75% after their Alzheimer's treatment failed in Phase 3 trials. The drug simufilam didn't show significant improvement in patients' cognition or function. SAVA stock crashed to a 4-year low. More updates to come.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing